The Current Ratio as of December 2024 (TTM) for Context Therapeutics Inc. (CNTX) is 36.91

According to Context Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 36.91. This represents a change of 35.47% compared to the average of 27.25 of the last 4 quarters.

Context Therapeutics Inc. (CNTX) Historical Current Ratio (quarterly & annually)

How has CNTX Current Ratio performed in the past?

The mean historical Current Ratio of Context Therapeutics Inc. over the last ten years is 6.51. The current 36.91 Current Ratio has changed 56.55% with respect to the historical average. Over the past ten years (40 quarters), CNTX's Current Ratio was at its highest in in the June 2024 quarter at 64.01. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Context Therapeutics Inc. (CNTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Context Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Context Therapeutics Inc. (CNTX) Average Current Ratio

How has CNTX Current Ratio performed in the past?

The current Current Ratio of Context Therapeutics Inc. (CNTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Context Therapeutics Inc. (CNTX) Current Ratio vs. Peers

How is CNTX’s Current Ratio compared to its peers?

Context Therapeutics Inc.’s Current Ratio is greater than Terns Pharmaceuticals, Inc. (32.99), greater than Amylyx Pharmaceuticals, Inc. (4.55), greater than Acumen Pharmaceuticals, Inc. (10.43), greater than Inozyme Pharma, Inc. (7.68), greater than X4 Pharmaceuticals, Inc. (4.89), greater than Spero Therapeutics, Inc. (2.68), greater than Bolt Biotherapeutics, Inc. (3.16), greater than Coherus BioSciences, Inc. (1.25), greater than Gracell Biotechnologies Inc. (7.73), greater than Neoleukin Therapeutics, Inc. (15.33), greater than Day One Biopharmaceuticals, Inc. (14.62), greater than VectivBio Holding AG (9.14), greater than NextCure, Inc. (9.07), greater than CytomX Therapeutics, Inc. (1.04), greater than Assembly Biosciences, Inc. (2.36), greater than Zura Bio Limited (10.36), greater than Annexon, Inc. (17.18), greater than Icosavax, Inc. (18.06), greater than IN8bio, Inc. (1.84), greater than Wave Life Sciences Ltd. (1.90),

Build a custom stock screener for Context Therapeutics Inc. (CNTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Context Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Context Therapeutics Inc. (CNTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Context Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.